OceanIQ Capital LLC Acquires New Holdings in Zoetis Inc. $ZTS

OceanIQ Capital LLC bought a new position in Zoetis Inc. (NYSE:ZTS) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 11,208 shares of the company’s stock, valued at approximately $845,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Prosperity Bancshares Inc bought a new position in Zoetis during the fourth quarter worth about $25,000. Cassaday & Co Wealth Management LLC acquired a new stake in shares of Zoetis during the first quarter worth about $28,000. Elyxium Wealth LLC bought a new position in shares of Zoetis during the 4th quarter valued at about $32,000. Root Financial Partners LLC grew its position in shares of Zoetis by 66.5% in the 1st quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock valued at $30,000 after purchasing an additional 103 shares during the period. Finally, Wellington Grp LLC increased its stake in Zoetis by 6,675.0% during the 1st quarter. Wellington Grp LLC now owns 271 shares of the company’s stock worth $32,000 after purchasing an additional 267 shares in the last quarter. 92.80% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several analysts have commented on ZTS shares. BNP Paribas Exane dropped their target price on shares of Zoetis from $146.00 to $110.00 and set an “outperform” rating on the stock in a report on Tuesday, August 11th. HSBC dropped their price objective on shares of Zoetis from $140.00 to $95.00 and set a “buy” rating on the stock in a report on Monday, July 6th. Zacks Research cut shares of Zoetis from a “hold” rating to a “strong sell” rating in a research report on Monday, August 10th. William Blair reaffirmed a “market perform” rating on shares of Zoetis in a research note on Thursday, August 6th. Finally, Weiss Ratings downgraded Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, June 12th. Eight research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $107.43.

Zoetis Trading Down 0.8%

ZTS opened at $75.70 on Friday. The company has a quick ratio of 1.84, a current ratio of 3.08 and a debt-to-equity ratio of 2.87. The stock has a market capitalization of $31.28 billion, a price-to-earnings ratio of 12.47, a P/E/G ratio of 1.78 and a beta of 0.73. The company has a 50-day simple moving average of $75.53 and a 200 day simple moving average of $93.85. Zoetis Inc. has a twelve month low of $71.00 and a twelve month high of $155.15.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.85 by $0.02. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The business had revenue of $2.47 billion for the quarter, compared to analysts’ expectations of $2.50 billion. During the same period last year, the firm posted $1.76 earnings per share. The firm’s quarterly revenue was down .2% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Analysts predict that Zoetis Inc. will post 6.2 EPS for the current fiscal year.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.